Filing Flows › Vertex Pharmaceuticals (VRTX) › Q2 2026
Vertex Pharmaceuticals (VRTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Vertex Pharmaceuticals (VRTX) reported revenue of $3.3B for the second quarter 2026 (Q2 2026), +12% from a year earlier and +12% from the quarter before. Operating margin was 37.4%, net earnings $1.1B (33.0% of revenue).
Vertex Pharmaceuticals, Q2 2026: revenue $3.3B (+12% year over year), operating margin 37.4%, net earnings $1.1B, operating cash flow $1.1B. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3B | +12% | +12% |
| Operating profit | $1.2B | +10% | +8% |
| Net earnings | $1.1B | +7% | +6% |
| Operating cash flow | $1.1B | -21% | +5% |
| Free cash flow | $1.0B | -22% | +9% |
What changed
Revenue was $3.3B in Q2 2026, up 12% year over year and up 12% from the previous quarter. TRIKAFTA/KAFTRIO was the largest line at 75% of revenue. ALYFTREK added $0.42B year over year (up 266%), 113% of the total change. Other CF product revenues declined 29%.
Operating profit was $1.2B, a 37.4% margin (down 1.4 points year over year). Of the extra revenue versus Q2 2025, 26% reached operating profit, below the 39% margin then. Total costs grew 15% against revenue growth of 12%. The fastest-growing cost line was SG&A (+37%). Net earnings were $1.1B, up 6% year over year. The effective tax rate was 21.0%.
Operating cash flow was $1.1B (up 5% year over year), 102% of net earnings. Non-cash charges added back $0.06B of depreciation and amortization and $0.17B of share-based compensation. Working capital and other items used $0.20B. Capital expenditures of $0.11B left free cash flow of $1.0B.
Questions
What was Vertex Pharmaceuticals' revenue in the second quarter 2026?
Vertex Pharmaceuticals (VRTX) reported revenue of $3.3B for the second quarter 2026 (Q2 2026), +12% from a year earlier and +12% from the quarter before.
Was Vertex Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $1.2B (37.4% of revenue) and net earnings $1.1B.